SCHEMBL30355387

SCHEMBL30355387

Cc1cnccc1-c1nc(-c2ccc3c(ccn3C(C)C)c2)no1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.47
RAB9A P51151 7/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
TP53 P04637 2/20 0.46
MAPT P10636 1/20 0.46
S1PR1 P21453 8/20 0.46
S1PR3 Q99500 2/20 0.44
TSHR P16473 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
AHR P35869 1/20 0.44
CYP11B1 P15538 2/20 0.42
CYP11B2 P19099 2/20 0.42
ALDH1A1 P00352 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23523738 1.00 NPC1 (0.47) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL23524313 0.88 NPC1 (0.43) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL30355539 0.86 S1PR1 (0.49) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL23524149 0.86 S1PR1 (0.49) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL30355372 0.85 NPC1 (0.49) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL23524328 0.85 NPC1 (0.49) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL30355414 0.83 NPC1 (0.52) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL23523934 0.83 NPC1 (0.52) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL23523941 0.82 NPC1 (0.57) NPC1RAB9ASMN1; SMN2TP53MAPT
SCHEMBL30355521 0.82 NPC1 (0.57) NPC1RAB9ASMN1; SMN2TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912693-B2 Compounds for modulating S1P1 activity and methods of using the same TREVENA, INC. (US) 2024-02-27 US disclosed
US-20230234946-A1 COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME TREVENA, INC. 2023-07-27 US disclosed
US-20230114241-A1 METHODS OF TREATING EPILEPSY USING THE SAME TREVENA, INC. 2023-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234946-A1 COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME S1PR1, S1PR2, S1PR3 NPC1 301/4885RAB9A 3056/4885MEN1 645/4885
US-20230114241-A1 METHODS OF TREATING EPILEPSY USING THE SAME S1PR1, S1PR2, S1PR3 NPC1 311/4885RAB9A 2056/4885MEN1 741/4885
US-11912693-B2 Compounds for modulating S1P1 activity and methods of using the same S1PR1, S1PR2, S1PR3 NPC1 301/4885RAB9A 3056/4885MEN1 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.